Botulinum toxin in patients at-risk for bladder augmentation: Durable impact or kicking the can?

Diana K BowenTheresa MeyerIlina RosoklijaRenea M SturmDavid I ChuEarl Y ChengElizabeth B Yerkes

Published in: Neurourology and urodynamics (2022)

Encouraging improvements in the urodynamic risk group were noted in some patients. With careful counseling and follow-up, BTX may safely extend the time to BA in some "at-risk" patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
botulinum toxin
prognostic factors
spinal cord injury
patient reported outcomes
smoking cessation
hepatitis c virus